NCT04269252终止2 期
A Randomized Controlled Test of the Effects of CHI-907 on Experiences of Test Anxiety Among College Students
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- Minimal single-dose of CHI-907 to reduce test anxiety
研究概览
简要总结
This is a randomized, placebo-controlled study examining the effects of CHI-907 on test anxiety specifically, and state anxiety more broadly.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult between 18 and 55-years-old (inclusive).
- •Willing and able to provide informed consent and attend a 2.5 hour, in-person session.
- •Self-reports completing a college-level introductory level statistics class with a grade of "C" or better.
- •Scores a 3.0 or higher on the Westside Test Anxiety Scale.
- •Female of childbearing potential must not be pregnant or currently breastfeeding.
- •If using medication, the student has maintained a stable regimen on existing medications for at least one month prior to participation in the study and throughout the study.
- •Agrees to abide by all study restrictions and comply with all study procedures.
排除标准
- •Known history of significant allergic condition, significant hypersensitivity to the IP, or allergic reaction to cannabis, cannabinoid medications, or excipients of the investigational product.
- •Exposed to any investigational drug or device < 30 days prior to screening or plans to take an investigational drug in the near future.
- •Used cannabis, synthetic cannabinoid or cannabinoid analogue, synthetic cannabinoid receptor agonist, or any CBD- or THC-containing product within 30 days of screening or during the study.
- •Current or past primary DSM-5 diagnosis other than an anxiety disorder that the Investigator determines would interfere in testing or interfere in evaluation of the study testing.
- •Total score of 8 or higher on the Alcohol Use Disorders Identification Test.
- •Total score of 12 or higher on the Drug Abuse Screening Test.
- •An acute or progressive disease that is likely to require changes in drug therapy during the study, or interfere with the objectives of the study, or the ability to adhere to protocol requirements.
- •Currently prescribed medications with likely THC- or CBD- interactions.
- •History of suicide attempt in the last year.
- •Endorses current suicidal intent during the baseline assessment.
- •Positive drug screen for THC, barbiturates, amphetamines, benzodiazepines, and/or opiates at baseline assessment.
- •Clinically significant condition or abnormal findings during screening or the baseline assessment that would, in the opinion of the Investigator, preclude study participation or interfere with the evaluation of the study testing.
- •Demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.
- •Female student of childbearing potential, unless willing to ensure that they or their partner use effective contraception during the study and for three months thereafter.
- •Male student whose partner is of childbearing potential, unless willing to ensure that they or their partner use effective contraception during the study and for three months thereafter.
- •Any other significant disease or disorder which, in the opinion of the investigator, may either put the student at risk because of participation in the study, may influence the result of the study, or affect the student's ability to participate in the study.
- •History of diagnosis related to hepatic function and/or significantly impaired hepatic function (alanine aminotransferase [ALT] >5 ´ upper limit of normal [ULN] or total bilirubin [TBL] >2 ´ ULN) OR the ALT or aspartate aminotransferase (AST) >3 ´ ULN and TBL >2 ´ ULN (or international normalized ratio [INR] >1.5).
- •Plans for the student to travel outside their country of residence during the study.
- •Body mass index (BMI) of underweight (18 kg/m2 and below) or obese (30 kg/m2 and above) or waist:hip ratio that is considered high health risk (0.86 and higher for women, 1.0 and higher for men).
结局指标
主要结局
Minimal single-dose of CHI-907 to reduce test anxiety
时间窗: The test session visit is 3.5 hours long.
Subjects will report their level of test anxiety using the State Test Anxiety Visual Analog Scale (STAI-VAS) pre-test, mid-test, and post-test. The STAI-VAS is a measure from 0 (not anxious at all) to 100 (anxious).
Optimal single-dose of CHI-907 to reduce test anxiety
时间窗: The test session visit is 3.5 hours long.
Subjects will report their level of test anxiety using the State Test Anxiety Visual Analog Scale (STAI-VAS) pre-test, mid-test, and post-test. The STAI-VAS is a measure from 0 (not anxious at all) to 100 (anxious).
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
A controlled study examining CBT for bereaved children.The death of a loved one in childhood and adolescence is a risk factor for distress and dysfunction. This event has been associated with increased emotional problems including elevated depression, anxiety, and posttraumatic stress, as well as somatic complaints and behavioural problems (Dowdney, 2008Kaplow, Layne, & Pynoos, 2012). An estimated 5% to 10% of children, experience clinically significant psychiatric problems following loss, including major depression, posttraumatic stress-disorder (PTSD), and Prolonged Grief Disorder (PGD) (Melhem, Moritz, Walker, Shear, & Brent, 2007Melhem, Porta, Shamseddeen, Walker, & Brent, 2011).PGD encompasses several symptoms including separation distress, preoccupation with thoughts about the lost person, a sense of purposelessness about the future, numbness, bitterness, difficulties accepting the loss and difficulty moving on with life without the lost person (Prigerson et al., 2009Shear et al., 2011). Although PGD has mostly been studied among adults, a growing body of empirical studies has shown that children and adolescents can develop PGD symptoms, that can be reliably assessed, are distinct from normal grief, depression and anxiety, including PTSD, and are predictive of significant concomitant internalizing and externalizing problems (Brown & Goodman, 2005Dillen, Fontaine, & Verhofstadt-Denève, 2008Spuij, Prinzie et al., 2012Spuij, Reitz et al., 2012). Evidence that, in a small percentage of people, acute grief reactions turn into chronic debilitating distress, blocking reestablishment of normal routines, will likely lead to the inclusion of two bereavement-related disorders in the DSM-5, namely Adjustment Disorder Related to Bereavement, located in its main text, and Persistent Complex Bereavement-Related Disorder, located in its appendix (APA, 2000APA, 2012for discussions see Boelen & Prigerson, 2012Kaplow et al., 2012Wakefield, 2012).NL-OMON25798niversiteit UtrechtFaculteit Sociale WetenschappenDepartement Kinder- en JeugdstudiesPostbus 801403508 TC UTRECHTNederland160
招募中
不适用
Randomised controlled trial to evaluate the effects of tele-monitoring weight in oncology and COPD patients.OncologyCOPD MalnutritionWeightInfectionsComplicationsNL-OMON24869Medizorg BVNutricia NetherlandsAbbott NutritionMedizorgLoodsboot 73991 CJ HoutenTel. +31 30 2804271 Nutricia NetherlandsAlbert Einsteinlaan 202719 EP Zoetermeer+31 79 3539000 Abbott NutritionWegalaan 92132 JD Hoofddorp+31 88 8222487168
尚未招募
不适用
A randomized, controlled study into the effects of food on the behaviour of young children with attention-deficit hyperactivity disorder (ADHD).NL-OMON2624980
尚未招募
4 期
Comparison of two concentrations of a drug in management of pain after brain surgeryCTRI/2023/12/060896ttar pradesh university of medical sceinces saifai etawah
尚未招募
3 期
To study whether pre-operative bathing with special emphasis on umbilicus cleaning and later on, cleaning with coconut oil decreases incidence of port site infection, wound complications and further development of hernias in patients undergoing laparoscopic cholecystectomyCTRI/2020/09/028110All India Institute of Medical Sciences